bupropion has been researched along with Binge-Eating Disorder in 6 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
Binge-Eating Disorder: A disorder associated with three or more of the following: eating until feeling uncomfortably full; eating large amounts of food when not physically hungry; eating much more rapidly than normal; eating alone due to embarrassment; feeling of disgust, DEPRESSION, or guilt after overeating. Criteria includes occurrence on average, at least 2 days a week for 6 months. The binge eating is not associated with the regular use of inappropriate compensatory behavior (i.e. purging, excessive exercise, etc.) and does not co-occur exclusively with BULIMIA NERVOSA or ANOREXIA NERVOSA. (From DSM-IV, 1994)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The authors tested the effectiveness of naltrexone-bupropion and behavioral weight loss therapy (BWL), alone and combined, for binge-eating disorder comorbid with obesity." | 9.51 | Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. ( Fineberg, SK; Grilo, CM; Gueorguieva, R; Ivezaj, V; Lydecker, JA; Moreno, JO, 2022) |
| " The new combination of naltrexone and bupropion sustained release (NB) has proved to be effective for weight loss among obese patients." | 9.41 | An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder. ( Aloi, M; Arturi, F; Calabrò, G; Carbone, EA; Caroleo, M; Condoleo, F; de Filippis, R; Rania, M; Segura-Garcia, C; Staltari, FA, 2021) |
| " The authors tested the effectiveness of naltrexone-bupropion and behavioral weight loss therapy (BWL), alone and combined, for binge-eating disorder comorbid with obesity." | 5.51 | Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. ( Fineberg, SK; Grilo, CM; Gueorguieva, R; Ivezaj, V; Lydecker, JA; Moreno, JO, 2022) |
| " The new combination of naltrexone and bupropion sustained release (NB) has proved to be effective for weight loss among obese patients." | 5.41 | An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder. ( Aloi, M; Arturi, F; Calabrò, G; Carbone, EA; Caroleo, M; Condoleo, F; de Filippis, R; Rania, M; Segura-Garcia, C; Staltari, FA, 2021) |
| " In BED with obesity or overweight, bupropion may cause mild weight loss without seizures, and chromium may improve glucose regulation." | 4.91 | Psychopharmacologic treatment of eating disorders: emerging findings. ( Guerdjikova, AI; Keck, PE; McElroy, SL; Mori, N, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grilo, CM | 2 |
| Lydecker, JA | 2 |
| Fineberg, SK | 1 |
| Moreno, JO | 1 |
| Ivezaj, V | 1 |
| Gueorguieva, R | 2 |
| Carbone, EA | 1 |
| Caroleo, M | 1 |
| Rania, M | 1 |
| Calabrò, G | 1 |
| Staltari, FA | 1 |
| de Filippis, R | 1 |
| Aloi, M | 1 |
| Condoleo, F | 1 |
| Arturi, F | 1 |
| Segura-Garcia, C | 1 |
| Morgan, PT | 1 |
| Guerdjikova, AI | 2 |
| Walsh, B | 1 |
| Shan, K | 1 |
| Halseth, AE | 1 |
| Dunayevich, E | 1 |
| McElroy, SL | 2 |
| Mori, N | 1 |
| Keck, PE | 1 |
| Calandra, C | 1 |
| Russo, RG | 1 |
| Luca, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo[NCT02317744] | 22 participants (Actual) | Interventional | 2014-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Binge eating will be assessed by interview and self-report and the primary outcome is frequency. Frequency also is defined continuously (analyzed dimensionally). (NCT02317744)
Timeframe: 6 month follow-up (an average of 6 months following treatment)
| Intervention | binge eating days (out of 28) (Mean) |
|---|---|
| Naltrexone/ Bupropion Combination | 5.4 |
| Pill Placebo | 2.9 |
Binge eating will be assessed by interview and self-report and the primary outcome is frequency. Frequency also is defined continuously (analyzed dimensionally). (NCT02317744)
Timeframe: Post-treatment (at 3 months)
| Intervention | binge eating days (out of 28) (Mean) |
|---|---|
| Naltrexone/ Bupropion Combination | 4.4 |
| Pill Placebo | 3.0 |
BMI is calculated using measured height and weight. (NCT02317744)
Timeframe: 6 month follow-up (an average of 6 months following treatment)
| Intervention | kg/m^2 (Mean) |
|---|---|
| Naltrexone/ Bupropion Combination | 35.9 |
| Pill Placebo | 40.3 |
BMI is calculated using measured height and weight. (NCT02317744)
Timeframe: Post-treatment (at 3 months)
| Intervention | kg/m^2 (Mean) |
|---|---|
| Naltrexone/ Bupropion Combination | 34.5 |
| Pill Placebo | 39.7 |
1 review available for bupropion and Binge-Eating Disorder
| Article | Year |
|---|---|
Psychopharmacologic treatment of eating disorders: emerging findings.
Topics: Administration, Intranasal; Anorexia Nervosa; Anti-Obesity Agents; Antidepressive Agents, Second-Gen | 2015 |
4 trials available for bupropion and Binge-Eating Disorder
| Article | Year |
|---|---|
Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial.
Topics: Behavior Therapy; Binge-Eating Disorder; Bupropion; Double-Blind Method; Female; Humans; Male; Middl | 2022 |
An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder.
Topics: Binge-Eating Disorder; Bupropion; Case-Control Studies; Feeding Behavior; Humans; Naltrexone; Weight | 2021 |
Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study.
Topics: Adult; Anti-Obesity Agents; Binge-Eating Disorder; Body Weight; Bupropion; Double-Blind Method; Drug | 2021 |
Bupropion versus sertraline in the treatment of depressive patients with binge eating disorder: retrospective cohort study.
Topics: Adult; Antidepressive Agents; Binge-Eating Disorder; Body Mass Index; Bupropion; Depressive Disorder | 2012 |
1 other study available for bupropion and Binge-Eating Disorder
| Article | Year |
|---|---|
Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Binge-Eating Disorder; Bup | 2017 |